Earnings Summary

Chinook Therapeutics Inc’s revenue fell -32.22% since last year same period to $1.83Mn in the Q1 2023. On a quarterly growth basis, Chinook Therapeutics Inc has generated 257.03% jump in its revenue since last 3-months.

Chinook Therapeutics Inc’s net profit fell -89.93% since last year same period to $-60.18Mn in the Q1 2023. On a quarterly growth basis, Chinook Therapeutics Inc has generated 3.8% jump in its net profits since last 3-months.

Chinook Therapeutics Inc’s net profit margin fell -180.22% since last year same period to -3291.96% in the Q1 2023. On a quarterly growth basis, Chinook Therapeutics Inc has generated 73.06% jump in its net profit margins since last 3-months.

Chinook Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.79 - a 0.37% jump from last quarter’s estimates.

Chinook Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.79.

Chinook Therapeutics Inc’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q1 2023. This indicates that the Chinook Therapeutics Inc has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Chinook Therapeutics Inc’s return on assets (ROA) stands at -0.24.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Chinook Therapeutics Inc’s return on equity (ROE) stands at -0.52.